Klaus Schwamborn is currently the Vice President in the Department of Vaccine Research at Valneva SE and serves as the Director of BlinK Biomedical SAS, France. He is involved in finding innovative approaches and technologies to generate novel vaccine candidates. He has also held international positions at Pepscan Therapeutics and Celgene. He has broad experience in drug discovery and research in infectious diseases and oncology including the areas of therapeutics antibodies and peptide based biologics. He received his PhD from the University of Göttingen and completed his Post-doctoral studies from the Institute Pasteur, Paris. Klaus Schwamborn is currently the Vice President in the Department of Vaccine Research at Valneva SE and serves as the Director of BlinK Biomedical SAS, France. He is involved in finding innovative approaches and technologies to generate novel vaccine candidates. He has also held international positions at Pepscan Therapeutics and Celgene. He has broad experience in drug discovery and research in infectious diseases and oncology including the areas of therapeutics antibodies and peptide based biologics. He received his PhD from the University of Göttingen and completed his Post-doctoral studies from the Institute Pasteur, Paris.

virology, vaccination and veterinary sciences